Fencamfamine

Fencamfamine
Systematic (IUPAC) name
N-ethyl-3-phenyl-norbornan-2-amine
Clinical data
Pregnancy cat.  ?
Legal status Schedule IV (USA)
Routes Oral
Pharmacokinetic data
Half-life 16 hours[1]
Identifiers
CAS number 2240-14-4
ATC code N06BA06
PubChem CID 14584
DrugBank DB01463
ChemSpider 13922 Y
UNII NME1I5IGBK Y
KEGG D07343 Y
ChEMBL CHEMBL7010 Y
Chemical data
Formula C15H21N 
Mol. mass 215.33 g/mol
SMILES eMolecules & PubChem
 Y(what is this?)  (verify)

Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed by Merck in the 1960s.[2]

Contents

Medical uses

Fencamfamine is still used, though rarely, for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, as its favourable safety profile makes it the most suitable drug in some cases.[3]

Adverse effects

Fencamfamine is well tolerated and causes minimal circulatory effects. Extended use may result in a dryness of the mouth. [3]

Contraindications

Not to be used with heart diseases, angina pectoris and decompensated cardiac insufficiency, glaucoma, hyper-excitability and thyrotoxicosis or while treated with monoamine oxidase inhibitors.[3]

Overdose

Symptoms of overdose are nausea, agitation and restlessness, dryness of the mouth, dizziness and tremor. In gross overdosage also associated with dyspnoea, tachycardia, disorientation and convulsions.[3]

Research

In a study on slices of rat corpus striatum and substantia nigra fencamfamine acted as an indirect dopamine agonist. It released dopamine by a similar mechanism to amphetamines, but was ten times less potent than dexamphetamine at producing this effect. The main mechanism of action was instead inhibition of dopamine reuptake. Also unlike amphetamines, fencamfamine does not inhibit the action of monoamine oxidase enzymes. It was concluded that, at least in the models employed, the in vitro profile of fencamfamine is more similar to that of nomifensine, a reportedly pure uptake inhibitor, than to d-amphetamine.[4]

In animal experiments on place preference fencamfamine produced a significant place preference only at the dose of 3.5 mg/kg. The experiments suggested a relation to dopamine D1 receptors, and also to opioid receptors in the reinforcement produced by fencamfamine, as place preference was blocked by the selective dopamine D1 antagonist SCH 23390 and by the opioid antagonist naloxone.[5] A similar place preference, which was blocked by naloxone and by SCH 23390 and by raclopride, has been seen in a study on rats with drinking water. Animals treated with naloxone before the conditioning sessions showed a place aversion instead of the place preference found in saline-treated animals. Naloxone also reduced drinking. It was proposed that naloxone induced a state of frustrative nonreward. It was suggested that both dopamine and (endogenous) opioids are important for water-induced reinforcement. Possible interactions between these two neurotransmitter systems were discussed.[6]

References

  1. ^ Delbeke, F. T.; Debackere, M. (1981). "Detection and metabolism of fencamfamine and the influence of acetazolamide on its urinary excretion". Biopharmaceutics & drug disposition 2 (1): 17–30. PMID 7236868.  edit
  2. ^ DE patent 1110159
  3. ^ a b c d REACTIVAN Tablets; REACTIVAN Syrup
  4. ^ Seyfried, C. A. (1983). "Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study". Biochemical pharmacology 32 (15): 2329–2331. doi:10.1016/0006-2952(83)90181-8. PMID 6136281.  edit
  5. ^ Planeta Cda, S.; Aizenstein, M. L.; Delucia, R. (1995). "Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors". Pharmacology, biochemistry, and behavior 50 (1): 35–40. doi:10.1016/0091-3057(94)00236-C. PMID 7700952.  edit
  6. ^ Agmo, A.; Federman, I.; Navarro, V.; Padua, M.; Velazquez, G. (1993). "Reward and reinforcement produced by drinking water: Role of opioids and dopamine receptor subtypes". Pharmacology, biochemistry, and behavior 46 (1): 183–194. PMID 8255911.  edit